PIA
SAGE

Piedmont Investment Advisors’s Sage Therapeutics SAGE Stock Holding History

Piedmont Investment Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,854
Closed -$278K – 876
2019
Q4 		$278K Buy
3,854
+131
+4% +$16.1K 0.01% 786
2019
Q3 		$522K Sell
3,723
-10
-0.3% -$1.67K 0.02% 505
2019
Q2 		$683K Buy
3,733
+228
+7% +$38.9K 0.03% 417
2019
Q1 		$557K Buy
3,505
+205
+6% +$29.7K 0.02% 488
2018
Q4 		$316K Buy
3,300
+12
+0.4% +$1.37K 0.02% 683
2018
Q3 		$464K Buy
+3,288
New +$508K 0.02% 558

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Piedmont Investment Advisors's SAGE Position: Q1 2020 in Review

Piedmont Investment Advisors sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 3,854 shares — an estimated $278K sold.

Piedmont Investment Advisors first reported a position in SAGE in Q3 2018 and held it in 6 quarters. The position peaked at $683K in Q2 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Piedmont Investment Advisors reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 3,854 Sage Therapeutics shares in Q1 2020, an estimated $278K.
  • Piedmont Investment Advisors first reported a position in Sage Therapeutics in Q3 2018 and held it in 6 quarters.
  • Piedmont Investment Advisors's Sage Therapeutics position peaked at $683K in Q2 2019.
  • 230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Piedmont Investment Advisors's 13F filing for Q1 2020, filed 12 May 2020.